Embattled Salix hires bankers to weigh a potential sale

Salix Pharmaceuticals ($SLXP) has taken a step toward a potential sale. Haunted by an inventory snafu and a C-suite shakeup, the company was already facing investor pressure to look for bidders once its supply issues were resolved. Now, Salix has tapped Crestview Partners to "explore options" as it hunts for a new CEO. No decision is expected until after that person comes on board, however. Report

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.